Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.

Live webcast of the presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917000487/en/

Investors:
888-969-7879
[email protected]

Media:
888-969-7879
[email protected]

Source: Travere Therapeutics, Inc.

You May Also Be Interested In

• CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
• Lantronix to Report Fiscal 2027 First Quarter Results on Nov. 9, 2026
• HONOR Announces Pre-Orders for HONOR X9e Pro, Breaking the Limits & Bringing Pro-Level Durability and Endurance